Management Raised The Bar For CVS Health Stock; Does The Chart Agree

On August 5, 2026, CVS Health (CVS) management raised its fiscal 2026 revenue forecast to at least $414 billion, up from $405 billion in May. Yet the stock has fallen 11.5% since the close prior to that release, compared with a 1.0% dip for the S&P 500. When a higher financial outlook meets a declining share price, investors should examine the technicals before taking the new numbers at face value. So does the CVS Health chart agree with the raise?

Partly: CVS Health Shares Fell But Trade Above Averages

The stock still trades above its key moving averages. CVS Health closed at $92.36 on October 16. That lands just above its 50-day average of $91.73, which tracks the closing price over the last 50 trading days. In turn, that figure sits above the 200-day average of $87.51, representing the average close across the last 200 trading days.

However, the return since the forecast update points the other way. The stock fell 7.9% in the two sessions around the release, while the S&P 500 slipped 0.3%. That market reaction priced the latest quarterly results and the new guide together. The shares then lost another 4.0% through October 16, underperforming a 0.7% dip for the broader index.

What CVS Health Management Raised For Fiscal 2026

The company upgraded its profit and cash targets as well. Management now expects adjusted EPS, an earnings measure the company defines itself, to land between $7.90 and $8.10. That is up from a prior target of $7.40, at the mid-point of the range. The company also projects cash flow from operations, the money generated by daily business activities, will reach at least $11.5 billion, compared with $9.5 billion previously. Executives credited this revision to strong performance so far in fiscal 2026. Furthermore, management noted that each operating segment grew earnings during the quarter ended June.

Part of that strength originated outside the three-month period itself. Management said items tied to earlier plan years contributed about $500 million, or 1.4 percentage points, to the medical benefit ratio. This metric tracks the share of premiums spent on medical care. The company also noted that some value initially expected in the second half of the year arrived early.

What Must CVS Health Deliver Before Fiscal 2026 Ends?

The short answer is less than it delivered a year ago. The higher forecast leaves about $207 billion of revenue to be recognized across the quarters ending September and December. That implies a figure about 0.5% less than CVS Health reported for the same two quarters of fiscal 2025. Revenue during the first half of the year grew 6.7% from a year earlier, so the updated guidance allows second-half revenue to slip below last year's pace.

Pharmacy is where management points to new business. On the August 5 call, management announced that eligible Zepbound and Foundayo patients will be able to pay cash for same-day pickup later in 2026, using either CVS Health's app or physical stores. The company also raised its fiscal 2026 forecast for adjusted operating income in the Pharmacy and Consumer Wellness segment to at least $6.4 billion.

Looking ahead to fiscal 2027, management expects a headwind in its pharmacy services business alongside membership declines at Caremark. Currently, the stock trades at 24.2 times reported earnings over the last twelve months. This multiple compares against 22.9 for the S&P 500 and relies on reported earnings rather than the adjusted measure used in the company guidance.

The outstanding questions are whether the remaining quarters can beat the elevated revenue target, and whether the pharmacy business maintains its growth. The risks to the stock are quarterly results falling short of guidance and the share price slipping below its two moving averages. Revenue for the quarter ended September remains the first major indicator to watch, with the report expected on November 4.

How To Act On CVS?

Not necessarily on CVS Health alone, if your goal is long-term wealth. Wealth is built by owning the companies that keep outperforming, the leaders of their industries, wherever they are. Here are two companies from CVS Health's own industry that have beaten it. Over the five years to October 2026, Quest Diagnostics stock rose 82% and DaVita stock rose 67%, while CVS Health stock rose 27%.

Finding companies like these takes comparison across industries and sectors, and that is what the Trefis High Quality (HQ) Portfolio does. It holds 30 quality companies in equal weight and, since its inception in September 2020, has returned more than 105%, ahead of a benchmark that combines the S&P 500, S&P Mid-cap and Russell 2000. See how we find the leaders.